The Claim
Combination therapy with photodynamic therapy and aflibercept is associated with a trend toward improved polyp regression and anatomical outcomes compared to aflibercept monotherapy in treatment-naïve polypoidal choroidal vasculopathy patients, but the differences are not statistically significant in the available evidence.
What the research says
Challenges is higher
Challenge is ahead, but a single strong supporting study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In patients with polypoidal choroidal vasculopathy who have not received prior treatment, combining photodynamic therapy with aflibercept shows a pattern of better polyp regression and anatomical outcomes than aflibercept alone, but the difference is not confirmed as statistically meaningful in current data.
See the scientific wording
Combination therapy with photodynamic therapy and aflibercept shows a trend toward improved polyp regression and anatomical outcomes compared to aflibercept monotherapy in treatment-naïve polypoidal choroidal vasculopathy patients, but these differences are not statistically significant in the available evidence.
Light-activated treatment destroys abnormal blood vessels in the eye, which lets a drug that blocks excess fluid growth work better by cleaning up the damaged vessels and making the remaining ones more stable.
What the research says
1 studyThe study found that adding PDT to aflibercept shots really does help shrink polyps and reduce fluid in the eye better than aflibercept alone — and the improvement was big enough to be sure it wasn't just luck. So the claim that it doesn't help is wrong.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.